Dear Fellow Shareholders of Nutra Pharma: As we are getting close to the end of the year, I wanted to take this opportunity to update you on the current status of the Company, provide a review of 2017 and briefly outline our goals and expectations for the coming months. Nutra Pharma Corporation operates as a biotechnology and biopharmaceutical company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the manageme

December 29, 2017 -- Coral Springs, Florida -- Nutra Pharma Corporation (OTC: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain announced today that the Company's Chief Executive Officer, Rik J Deitsch, has published a Shareholder Letter on the Company's website. “